Repeated changes of the molecular subtype in gastric metastasis from breast cancer: A case report

Nakamura,Jun; Okuyama,Keiichiro; Sato,Hirofumi; Yoda,Yukie; Kai,Keita; Noshiro,Hirokazu

doi:10.3892/mco.2016.795

Repeated changes of the molecular subtype in gastric metastasis from breast cancer: A case report

Authors:
- Jun Nakamura
- Keiichiro Okuyama
- Hirofumi Sato
- Yukie Yoda
- Keita Kai
- Hirokazu Noshiro
View Affiliations

Affiliations: Department of Surgery, Saga University Faculty of Medicine, Saga 849‑8501, Japan, Department of Pathology, Saga University Hospital, Saga 849‑8501, Japan
Published online on: March 1, 2016 https://doi.org/10.3892/mco.2016.795
Pages: 695-698

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric metastasis from breast cancer is clinically diagnosed rarely. The present study described an interesting and valuable case of gastric metastasis from breast cancer, which showed repeated changes of the molecular subtype with an impact on the choice of treatment. A 42‑year‑old woman underwent mastectomy with axillary lymph node dissection for an invasive lobular carcinoma of the left breast. The patient received gastroscopy due to an epigastric pain during the adjuvant chemotherapy. The endoscopic examination revealed an erosive lesion at the posterior wall of the gastric body. The gastric lesion was immunohistochemically diagnosed as a metastatic disease from the breast cancer. The patient initially received hormone therapy, according to the subtype of the primary and the metastatic diseases. The gastric lesion initially disappeared; however, a relapsed lesion transformed into luminal human epidermal growth factor receptor 2 type from luminal type. Subsequently, the metastatic lesions underwent repeated subtype changing, which created difficultly when deciding the treatment strategy. The molecular profile of breast cancer can change during the treatment, resulting in the treatment resistance observed in certain cases. Therefore, the optimal treatment must be selected, according to the changed subtype.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:530–536. 2002. View Article : Google Scholar : PubMed/NCBI
3	Guarneri V and Conte P: Metastatic breast cancer: Therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist. 14:645–656. 2009. View Article : Google Scholar : PubMed/NCBI
4	Greene FL: Breast tumours. TNM classification of malignant tumours. Sobin LH, Gospodarowicz MK and Wittekind C: (7th ed). Wiley-Blackwell. (Oxford). 181–93. 2009.
5	Hoff J, Portet R, Becue J, Fourtanier G and Bugat R: Digestive tract metastases of breast cancers. Ann Chir. 37:281–284. 1983.(In French). PubMed/NCBI
6	Borst MJ and Ingold JA: Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. Surgery. 114:637–641; discussion 641–642. 1993.PubMed/NCBI
7	Washington K and McDonagh D: Secondary tumors of the gastrointestinal tract: Surgical pathologic findings and comparison with autopsy survey. Mod Pathol. 8:427–433. 1995.PubMed/NCBI
8	Caramella E, Bruneton JN, Roux P, Aubanel D and Lecomte P: Metastases of the digestive tract. Report of 77 cases and review of the literature. Eur J Radiol. 3:331–338. 1983.PubMed/NCBI
9	Wang Z, Spaulding B, Sienko A, Liang Y, Li H, Nielsen G, Gong Yub G, Ro JY and Zhai Jim Q: Mammaglobin, a valuable diagnostic marker for metastatic breast carcinoma. Int J Clin Exp Pathol. 2:384–389. 2009.PubMed/NCBI
10	Takeda Y, Tsuta K, Shibuki Y, Hoshino T, Tochigi N, Maeshima AM, Asamura H, Sasajima Y, Ito T and Matsuno Y: Analysis of expression patterns of breast cancer-specific markers (mammaglobin and gross cystic disease fluid protein 15) in lung and pleural tumors. Arch Pathol Lab Med. 132:239–243. 2008.PubMed/NCBI
11	Raju U, Ma CK and Shaw A: Signet ring variant of lobular carcinoma of the breast: A clinicopathologic and immunohistochemical study. Mod Pathol. 6:516–520. 1993.PubMed/NCBI
12	Wick MR, Lillemoe TJ, Copland GT, Swanson PE, Manivel JC and Kiang DT: Gross cystic disease fluid protein-15 as a marker for breast cancer: Immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. Hum Pathol. 20:281–287. 1989. View Article : Google Scholar : PubMed/NCBI
13	Schwarz RE, Klimstra DS and Turnbull AD: Metastatic breast cancer masquerading as gastrointestinal primary. Am J Gastroenterol. 93:111–114. 1998. View Article : Google Scholar : PubMed/NCBI
14	Pectasides D, Psyrri A, Pliarchopoulou K, Floros T, Papaxoinis G, Skondra M, Papatsibas G, Macheras A, Athanasas G, Arapantoni-Datioti P and Economopoulos T: Gastric metastases originating from breast cancer: Report of 8 cases and review of the literature. Anticancer Res. 29:4759–4763. 2009.PubMed/NCBI
15	García-Becerra R, Santos N, Díaz L and Camacho J: Mechanisms of resistance to endocrine therapy in breast cancer: Focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci. 14:108–145. 2012. View Article : Google Scholar : PubMed/NCBI
16	Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK and Dowsett M: Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2 and p38 mitogen-activated protein kinase. J Clin Oncol. 23:2469–2476. 2005. View Article : Google Scholar : PubMed/NCBI
17	Yang YF, Liao YY, Li LQ, Xie SR, Xie YF and Peng NF: Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer. Pathol Res Pract. 209:797–802. 2013. View Article : Google Scholar : PubMed/NCBI
18	Pohlmann PR, Mayer IA and Mernaugh R: Resistance to trastuzumab in breast cancer. Clin Cancer Res. 15:7479–7491. 2009. View Article : Google Scholar : PubMed/NCBI
19	Guarneri V, Dieci MV, Barbieri E, Piacentini F, Omarini C, Ficarra G, Bettelli S and Conte PF: Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. Ann Oncol. 24:2990–2994. 2013. View Article : Google Scholar : PubMed/NCBI
20	Hirata T, Shimizu C, Yonemori K, Hirakawa A, Kouno T, Tamura K, Ando M, Katsumata N and Fujiwara Y: Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. Br J Cancer. 101:1529–1536. 2009. View Article : Google Scholar : PubMed/NCBI